THE CARDIOVASCULAR MARKET IN ROMANIA DURING 1998 - 2017
PERIOD – ANALYSIS AND EVOLUTION
MARIAN PANĂ 1#, PETRU CRĂCIUN 1#, CAMELIA NICOLAE 2#, ADRIANA-ELENA TĂEREL 3*, DUMITRU LUPULIASA 1
1Pharmaceutical Technology and Biopharmacy Department, Faculty of Pharmacy, “Carol Davila” University of Medicine
and Pharmacy, Bucharest, Romania
2Cardiology Department, Panduri Hospital, Bucharest, Romania
3Department of Pharmaceutical Management and Marketing, Faculty of Pharmacy, University of Medicine and Pharmacy
“Carol Davila”, Bucharest, Romania
*corresponding author: adriana.taerel@yahoo.com
#Authors with equal contribution
Download Full Article

Abstract:
By all dimensions of analysis: units, DOT and values, the cardiovascular market has grown significantly over the last twenty
years. However, it is still questionable if this development is enough, as cardiovascular diseases account for the most
important mortality factor in Romania. Concerning therapeutic groups, of used cardiovascular drugs the biggest share in days
of treatment belongs to C9 (inhibitors of the renin-angiotensin system), followed at certain distance by C10 (anti-atheroma
agents and lipid regulators), C1 (cardiac therapy), C7 (beta-blocking agents), C8 (calcium antagonists) and C3 (diuretics).
Regarding channels, retail channel accounts for dispensing almost all cardiovascular drugs. By administration route, oral
solid forms are by far the most used form. Taking into consideration the product type, generic medicines are dominating in
volume, while original medicines leads in value. Concerning market layers, volume and value of cardiovascular drugs are
balanced between the 3 layers, while almost 2/3 of the population stays in the 3rd layer, which raises questions about the
treatment accessibility in small cities and villages. Regarding INNs, there is a significant dynamic over the time; currently the
most used are metoprolol, indapamide and atorvastatin.

Top